Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy

By Bolli N.   Di Ianni M.   Simonetti S.   Cerroni L.   Liso A.   Falini B.   Tabilio A.  

Lancet Oncology, Vol. 5, Iss. 1, 2004-01 ,pp. : 64-65

Elsevier

Access to resources Recommend Favorite

Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1

By  

Current Cancer Therapy Reviews, Vol. 8, Iss. 1, 2012-02 ,pp. : 44-51

Bentham Science Publishers

Access to resources Recommend Favorite

Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome

By Montillo Marco   Schinkoethe Timo   Elter Thomas  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 488-496

Informa Healthcare

Access to resources Recommend Favorite

Recent trends and future projections of lymphoid neoplasms – a Bayesian age–period–cohort analysis

By Bray I.  

Cancer Causes and Control, Vol. 12, Iss. 9, 2001-11 ,pp. : 813-820

Springer Publishing Company

Access to resources Recommend Favorite

Body mass index, height and risk of lymphoid neoplasms in a large United States cohort

By Patel Alpa V.  

Leukemia and Lymphoma, Vol. 54, Iss. 6, 2013-06 ,pp. : 1221-1227

Informa Healthcare

Access to resources Recommend Favorite